Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT.

Das JP, Halpenny D, Do RK, Ulaner GA.

Clin Nucl Med. 2019 Oct;44(10):836-837. doi: 10.1097/RLU.0000000000002692.

PMID:
31283599
2.

PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?

Ulaner GA.

AJR Am J Roentgenol. 2019 Aug;213(2):254-265. doi: 10.2214/AJR.19.21177. Epub 2019 May 7.

PMID:
31063423
3.

Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM.

Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.

4.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
5.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
6.

Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Ulaner GA, Bodei L.

Clin Nucl Med. 2019 Apr;44(4):330-331. doi: 10.1097/RLU.0000000000002467.

PMID:
30688738
7.

ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast.

Expert Panel on Breast Imaging:, Niell BL, Lourenco AP, Moy L, Baron P, Didwania AD, diFlorio-Alexander RM, Heller SL, Holbrook AI, Le-Petross HT, Lewin AA, Mehta TS, Slanetz PJ, Stuckey AR, Tuscano DS, Ulaner GA, Vincoff NS, Weinstein SP, Newell MS.

J Am Coll Radiol. 2018 Nov;15(11S):S313-S320. doi: 10.1016/j.jacr.2018.09.017.

PMID:
30392600
8.

Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists.

Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, Balachandran V, Giancipoli RG, Monti S, Mannelli L.

Abdom Radiol (NY). 2019 Feb;44(2):586-592. doi: 10.1007/s00261-018-1765-z.

PMID:
30251132
9.

18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.

Ulaner GA, Juarez J, Riedl CC, Goldman DA.

J Nucl Med. 2019 Apr;60(4):472-477. doi: 10.2967/jnumed.118.217836. Epub 2018 Sep 20.

PMID:
30237211
10.

Uses and Opportunities for Molecular Imaging in Patients with Breast Cancer.

McDonald ES, Ulaner GA.

PET Clin. 2018 Jul;13(3):xi-xii. doi: 10.1016/j.cpet.2018.05.001. No abstract available.

PMID:
30100083
11.

Amino Acid Metabolism as a Target for Breast Cancer Imaging.

Ulaner GA, Schuster DM.

PET Clin. 2018 Jul;13(3):437-444. doi: 10.1016/j.cpet.2018.02.009. Review.

12.

Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Henry KE, Ulaner GA, Lewis JS.

PET Clin. 2018 Jul;13(3):423-435. doi: 10.1016/j.cpet.2018.02.010. Review.

13.

Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.

Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R.

PET Clin. 2018 Jul;13(3):355-361. doi: 10.1016/j.cpet.2018.02.011. Review.

PMID:
30100075
14.

Molecular Classification of Breast Cancer.

Provenzano E, Ulaner GA, Chin SF.

PET Clin. 2018 Jul;13(3):325-338. doi: 10.1016/j.cpet.2018.02.004. Epub 2018 May 7. Review.

PMID:
30100073
15.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

16.

Mazabraud's Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer.

Mahajan S, Goel R, Riedl C, Ulaner GA.

Clin Nucl Med. 2018 Aug;43(8):625-626. doi: 10.1097/RLU.0000000000002151.

PMID:
29863575
17.

Trends in oncologic hybrid imaging.

Wibmer AG, Hricak H, Ulaner GA, Weber W.

Eur J Hybrid Imaging. 2018;2(1):1. doi: 10.1186/s41824-017-0019-6. Epub 2018 Jan 19. Review.

18.

90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material.

Kurilova I, Beets-Tan RGH, Ulaner GA, Boas FE, Petre EN, Yarmohammadi H, Ziv E, Deipolyi AR, Brody LA, Gonen M, Sofocleous CT.

Cardiovasc Intervent Radiol. 2018 Sep;41(9):1419-1427. doi: 10.1007/s00270-018-1985-1. Epub 2018 May 15.

PMID:
29766239
19.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12.

20.

Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management.

Sawan P, Rebeiz K, Schoder H, Batlevi C, Moskowitz A, Ulaner GA, Dunphy M, Mannelli L.

Medicine (Baltimore). 2017 Dec;96(51):e9411. doi: 10.1097/MD.0000000000009411.

21.

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA.

J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16.

22.

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA.

Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.

23.

Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.

Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB.

J Nucl Med. 2018 Mar;59(3):399-402. doi: 10.2967/jnumed.117.194480. Epub 2017 Aug 17.

24.

David Versus the Goliaths for the Detection of Bone Metastases.

Ulaner GA.

J Nucl Med. 2017 Nov;58(11):1776-1777. doi: 10.2967/jnumed.117.199893. Epub 2017 Aug 17. No abstract available.

25.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

27.

Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma.

Ulaner GA, Healey JH, Athanasian EA.

Clin Orthop Relat Res. 2017 Sep;475(9):2274-2279. doi: 10.1007/s11999-017-5388-4. Epub 2017 May 23.

28.

Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, Gönen M, Dickler M, Weber WA.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1428-1437. doi: 10.1007/s00259-017-3703-7. Epub 2017 May 1.

29.

18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.

Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1420-1427. doi: 10.1007/s00259-017-3709-1. Epub 2017 Apr 29.

PMID:
28456837
30.

Value of second-opinion review of outside institution PET-CT examinations.

Ulaner GA, Mannelli L, Dunphy M.

Nucl Med Commun. 2017 Apr;38(4):306-311. doi: 10.1097/MNM.0000000000000647.

31.

Transient Osteoporosis of the Hip on FDG PET/CT.

Ulaner GA, Sawan P.

Clin Nucl Med. 2017 May;42(5):401-402. doi: 10.1097/RLU.0000000000001630.

32.

FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.

Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH.

Clin Nucl Med. 2017 Apr;42(4):264-270. doi: 10.1097/RLU.0000000000001580.

33.

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2017 Jun 15;23(12):3053-3060. doi: 10.1158/1078-0432.CCR-16-2197. Epub 2016 Dec 23. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1435.

34.

Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers.

Ulaner GA, Goldman DA, Corben A, Lyashchenko SK, Gönen M, Lewis JS, Dickler M.

J Nucl Med. 2017 Jul;58(7):1037-1042. doi: 10.2967/jnumed.116.183335. Epub 2016 Nov 17.

35.

FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate.

Hogan MP, Osborne J, Ulaner GA.

Clin Nucl Med. 2016 Dec;41(12):995-997.

36.

Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome.

Ulaner GA, Samstein R, Cahlon O, Weber WA, Rimner A.

Clin Nucl Med. 2016 Oct;41(10):797-8. doi: 10.1097/RLU.0000000000001319.

PMID:
27454597
37.

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.

Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, Weber WA.

Am J Nucl Med Mol Imaging. 2016 Apr 24;6(2):120-7. eCollection 2016.

38.

Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT.

Eur J Radiol. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31.

39.

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.

Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA.

J Nucl Med. 2016 Oct;57(10):1523-1528. Epub 2016 May 5.

40.

(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.

Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1937-44. doi: 10.1007/s00259-016-3402-9. Epub 2016 Apr 30.

41.

The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.

Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, Dickler M, Gönen M, Weber WA.

J Nucl Med. 2016 Jul;57(7):1102-4. doi: 10.2967/jnumed.115.166629. Epub 2016 Mar 16.

42.

Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.

Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C.

J Nucl Med. 2016 Sep;57(9):1350-6. doi: 10.2967/jnumed.115.170456. Epub 2016 Mar 3.

43.

Molecular Imaging of Biomarkers in Breast Cancer.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W.

J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S. doi: 10.2967/jnumed.115.157909. Review.

44.

Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI.

Jochelson MS, Lebron L, Jacobs SS, Zheng J, Moskowitz CS, Powell SN, Sacchini V, Ulaner GA, Morris EA, Dershaw DD.

AJR Am J Roentgenol. 2015 Oct;205(4):899-904. doi: 10.2214/AJR.14.13804.

45.

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.

J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.

47.

Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered?

Ulaner GA, Riedl CC.

J Nucl Med. 2015 Aug;56(8):1293-4. doi: 10.2967/jnumed.115.161042. Epub 2015 Jun 25. No abstract available.

48.

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Ulaner GA, Goldman DA, Sauter CS, Migliacci J, Lilienstein J, Gönen M, Schöder H, Moskowitz CH, Zelenetz AD.

Radiology. 2015 Nov;277(2):518-26. doi: 10.1148/radiol.2015142556. Epub 2015 Jun 2.

49.

Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.

Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, Hudis CA, Morrow M, Ulaner GA.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1666-1673. doi: 10.1007/s00259-015-3080-z. Epub 2015 May 14.

50.

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH.

Blood. 2015 Apr 16;125(16):2579-81. doi: 10.1182/blood-2014-10-606939. Epub 2015 Mar 10.

Supplemental Content

Loading ...
Support Center